All posts tagged "Novo Nordisk"

This article originally appeared in OpenSecrets. Sign up for their weekly newsletter to receive stories like this one in your inbox.

Novo Nordisk — the pharmaceutical giant behind popular weight-loss drugs Ozempic and Wegovy — spent a record $3.2 million on lobbying in the first six months of 2024 as the Denmark-based company expanded its footprint in the United States.

In 2017, after two years of clinical trials, the Food and Drug Administration approved Novo Nordisk’s injectable weight-loss drug Ozempic strictly for adults with Type 2 diabetes. Four years later, the FDA approved Wegovy, another weight-loss drug that is not strictly for type 2 patients but contains the same active ingredient as Ozempic, semaglutide....

WASHINGTON — The US Supreme Court ruled that generic drug makers can challenge big-name pharmaceutical firms in court to stop them from broadening the scope of their patent descriptions.